Amgen, Inc. vs CleanSpark Inc — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while CleanSpark Inc trades at $12.17 (market cap $2.96B). The key difference: Amgen, Inc. is far larger — about 75.7× CleanSpark Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while CleanSpark Inc pays none. Which is the better fit depends on your goals.
| AMGN | CLSK | |
|---|---|---|
Market Cap | $224.14B | $2.96B |
Sector | Health | Technology |
52-Week High | $417.20 | $23.20 |
52-Week Low | $271.18 | $8.18 |
Enterprise Value | $267.45B | $3.95B |
Dividend Yield | 2.43% | — |
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
CleanSpark trades at $12.18, up 5.09% today but facing bearish technical signals with 17 sell indicators versus 5 buy signals. The company reported four consecutive quarterly earnings misses, with Q2 2026 showing a loss of $0.89 per share versus expectations of -$0.47. Despite negative profitability metrics including a -146.9% net income margin, analysts maintain unanimous buy ratings with a $24.13 consensus price target, representing 98% upside potential. Recent news highlights a strategic pivot to AI data centers through a $6.6 billion, 20-year lease agreement.
The stock presents a high-risk, high-reward opportunity with strong analyst conviction contrasting weak fundamentals. The AI data center expansion offers significant long-term revenue potential but requires substantial capital investment amid current cash flow challenges. Key risks include execution of the strategic pivot, continued earnings volatility, and the need for additional financing to support growth initiatives.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →CleanSpark is a leading Bitcoin mining company that operates high-density data centers. It focuses on using sustainable energy to power its mining fleet and provides digital infrastructure for the blockchain ecosystem.
Read more on CLSK →